<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Clin Pract</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Clin Pract</journal-id>
<journal-id journal-id-type="hwp">neurclinpract</journal-id>
<journal-id journal-id-type="publisher-id">neucp</journal-id>
<journal-id journal-id-type="pmc">neurclinpract</journal-id>
<journal-id journal-id-type="publisher-id">NEURCLINPRACT</journal-id>
<journal-title-group>
<journal-title>Neurology: Clinical Practice</journal-title>
</journal-title-group>
<issn pub-type="ppub">2163-0402</issn>
<issn pub-type="epub">2163-0933</issn>
<publisher>
<publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
<publisher-loc>Hagerstown, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27104068</article-id>
<article-id pub-id-type="pmc">4828678</article-id>
<article-id pub-id-type="publisher-id">NEURCLINPRACT2015012765</article-id>
<article-id pub-id-type="doi">10.1212/CPJ.0000000000000239</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>91</subject>
<subject>110</subject>
<subject>111</subject>
<subject>325</subject>
<subject>329</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical exome sequencing in neurologic disease</article-title>
<subtitle>AAN model coverage policy</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fogel</surname>
<given-names>Brent L.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>1. American Academy of Neurology, Speaker Honoraria 2. American Physician Institute for Advanced Professional Studies, Travel and Speaker Honoraria 3. National Ataxia Foundation, Travel</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>American Physician Institute for Advanced Professional Studies, Travel and Speaker Honoraria</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>National Institutes of Health NIH/NINDS 5 R01 NS082094 (PI Fogel) 04/2013 - 03/2018 NIH/NIMH 5 K08 MH086297 (PI Fogel) 07/2009-04/2014</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>National Ataxia Foundation (PI Fogel) 01/2012 - 01/2013</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Satya-Murti</surname>
<given-names>Saty</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Between January 2013 and July 2015 I have participated in telephone consultations and/or in-person Medical Advisory Board meetings for: (1)Evidera (formerly United BioSource Corporation UBC)(2)Simon-Kucher consultants (3) Covidien (4) Baxter (5) Shire (6) Stratas Consultants,(7)AstraZeneca (8)Avalere LLC, (9)AbioMed, and(10) 1798 Consultants</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>Travel expenses: (1)United BioSource Corporation UBC (2010-13)(2)AstraZeneca (3)Avalere LLC, (4) Evidera consulting group, (5) Covidien, (6) Michael J. Fox Foundation, (7) Foley Hoag LLP, (8) Baxter</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Neurology: Clinical Practice Editorial Board Member. Appointed in early 2014.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Commercial:(1)Evidera (formerly United BioSource Corporation UBC)(2)Simon-Kucher consultants (3) Covidien (4) Baxter (5) Shire (6) Stratas Consultants,(7)AstraZeneca (8)Avalere LLC, (9)AbioMed, and(10) 1798 Consultants. Non-profit: Michael J. Fox Foundation.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>Panelist, and later (2010-2011) Vice-Chair CMS-Medcac (Medicare Evidence Development and Coverage Advisory Committee). For the duration of the Medcac meeting, usually 1-2 days, I was considered an SGE (Special Government Employee). I was a member of the AAN Payment Policy Subcommittee (PPS)from 2006 to 2011. Non-financial disclosures: I was asked in Jan. 2010 to advice and represent a device manufacturing company on preparing a response to AAN's position on TENS and back pain treatment. I spoke to them and declined their offer of a consulting fee or representation. My policy, written as a former Medicare Medical Director, concerning IVIg use in adults with immunodeficiency and HIV or AIDS became the subject of discord with one provider. This issue was also handled by CMS. It has not been active since 2005-6. This matter, even if it were active, is NOT THE subject of the current paper.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cohen</surname>
<given-names>Bruce H.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>DSMB-Stem Cell Transplantation for MNGIE (non-profit) Chairman-External Advisory Board of Clinical Protocols, Neurofibromatosis Consortium, Department of Defense</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>Honoraria from the AAN for speaking activities and serving on committees</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Editorial Board for Pediatric Neurology Editorial Board for Mitochondrion</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>Akron Children's Hospital, Director of The NeuroDevelopmental Science Center and Director of Neurology, 5 years. Primary Employer</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Motive Medical Intelligence; content editor (formally known as New Mentor), commercial Stealth Biotherapeutics: Commercial Mitobridge: Commercial</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>Speakers Bureau: Transgenomic Labs (commercial); payments for speaking paid to my primary employer Speakers Bureau: Courtagen Labs (commercial); payments for speaking paid to my primary employer Speakers Bureau: United Mitochondrial Disease Foundation(non-profit) Courtagen Labs</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>I am a consultant to Health and Human Services for the Division of Vaccine Injury Compensation Program.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Edison Pharmaceuticals, Raptor Pharmaceuticals, Stealth Biotherapeutics and Reata Pharma. I have received reimbursement for travel expenses related to scientific study management but have not received any financial incentive or money or research support or salary support. My hospital does have a contract with these companies for conducting research but I accept no specific salary support or accept money outside of this contract.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>I am a consultant to Health and Human Services for the Vaccine Compensation Program and review cases and intend to provide testimony in the future. NIH</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>United Mitochondrial Disease Foundation, Board of Trustees</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>I am a consultant to Health and Human Services for the Division of Vaccine Injury Compensation Program; Government 2008-present Various Medical-Legal Cases; expert witness for defense, current</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>Program in Neurogenetics and Departments of Neurology and Human Genetics (BLF), David Geffen School of Medicine, University of California Los Angeles; Health Policy Consultant (SS-M), Santa Maria, CA; and NeuroDevelopmental Science Center and the Department of Pediatrics (BHC), Akron Children's Hospital, OH.</aff>
</contrib-group>
<author-notes>
<corresp>
<bold>Correspondence to:</bold>
<email>bfogel@ucla.edu</email>
</corresp>
<fn fn-type="financial-disclosure">
<p>Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the <ext-link ext-link-type="uri" xlink:href="http://cp.neurology.org/lookup/doi/10.1212/CPJ.0000000000000239"><bold>full text of this article at Neurology.org/cp</bold></ext-link>.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<month>4</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
<volume>6</volume>
<issue>2</issue>
<fpage>164</fpage>
<lpage>176</lpage>
<history>
<date date-type="received">
<day>27</day>
<month>9</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>12</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 American Academy of Neurology</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
</permissions>
<self-uri xlink:href="NEURCLINPRACT2015012765.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<sec>
<title>Purpose of review:</title>
<p>The landscape of genetic diagnostic testing has changed dramatically with the introduction of next-generation clinical exome sequencing (CES), which provides an unbiased analysis of all protein-coding sequences in the roughly 21,000 genes in the human genome. Use of this testing, however, is currently limited in clinical neurologic practice by the lack of a framework for appropriate use and payer coverage.</p>
</sec>
<sec>
<title>Recent findings:</title>
<p>CES can be cost-effective due to its high diagnostic yield in comparison to other genetic tests in current use and should be utilized as a routine diagnostic test in patients with heterogeneous neurologic phenotypes facing a broad genetic differential diagnosis. CES can eliminate the need for escalating sequences of conventional neurodiagnostic tests.</p>
</sec>
<sec>
<title>Summary:</title>
<p>This review discusses the role of clinical exome sequencing in neurologic disease, including its benefits to patients, limitations, appropriate use, and billing. We also provide a reference template policy for payer use when considering testing requests.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>